title: Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
abstract: The alarming global rise of antimicrobial resistance combined with the lack of new antimicrobial agents has led to a renewed interest in optimization of our current antibiotics. Continuous infusion (CI) of time-dependent antibiotics has certain theoretical advantages toward efficacy based on pharmacokinetic/pharmacodynamic principles. We reviewed the available clinical studies concerning continuous infusion of beta-lactam antibiotics and vancomycin in critically ill patients. We conclude that CI of beta-lactam antibiotics is not necessarily more advantageous for all patients. Continuous infusion is only likely to have clinical benefits in subpopulations of patients where intermittent infusion is unable to achieve an adequate time above the minimal inhibitory concentration (T > MIC). For example, in patients with infections caused by organisms with elevated MICs, patients with altered pharmacokinetics (such as the critically ill) and possibly also immunocompromised patients. For vancomycin CI can be chosen, not always for better clinical efficacy, but because it is practical, cheaper, associated with less AUC24h (area under the curve >24 h)-variability, and easier to monitor.
authors: Department of Microbiology, Antwerp University Hospital, Edegem, Belgium. Bruno.van.herendael@uza.be.
authors: Bruno
authors: B
authors: Van Herendael
authors: Axel
authors: A
authors: Jeurissen
authors: Paul M
authors: PM
authors: Tulkens
authors: Erika
authors: E
authors: Vlieghe
authors: Walter
authors: W
authors: Verbrugghe
authors: Philippe G
authors: PG
authors: Jorens
authors: Margareta
authors: M
authors: Ieven